Parkinson disease is a clinicopathological construct at a crossroads. A new study reinforces the prognostic value of subtypes, but its findings challenge the relevance of pathology to the clinical expression of disease as data-driven Parkinson disease subtypes did not match up with severity or distribution of Lewy or Alzheimer pathologies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marras, C. Subtypes of Parkinson’s disease: state of the field and future directions. Curr. Opin. Neurol. 28, 382–386 (2015).
Zetusky, W. J., Jankovic, J. & Pirozzolo, F. J. The heterogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 35, 522–526 (1985).
Simuni, T. et al. How stable are Parkinson’s disease subtypes in de novo patients: analysis of the PPMI cohort? Parkinsonism Relat. Disord. 28, 62–67 (2016).
Mestre, T. A. et al. Reproducibility of data-driven Parkinson’s disease subtypes for clinical research. Parkinsonism Relat. Disord. 56, 102–106 (2018).
Marras, C. & Lang, A. Parkinson’s disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84, 409–415 (2013).
Selikhova, M. et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132, 2947–2957 (2009).
Fereshtehnejad, S. M. et al. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140, 1959–1976 (2017).
De Pablo-Fernández, E. et al. Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2018.4377 (2019).
Espay, A. J. et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92, 1–10 (2019).
Espay, A. J. et al. Biomarker-driven phenotyping in Parkinson’s disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319–324 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J.E. has received grant support from the NIH, Great Lakes Neurotechnologies and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Impax, Sunovion, Lundbeck, Osmotica Pharmaceutical and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press and Springer; and honoraria from USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology and the Movement Disorders Society. C.M. has received grant support from the Michael J. Fox Foundation, the Canadian Institutes of Health Research, Parkinson Foundation (US), the International Parkinson and Movement Disorders Society and the NIH, is a member of the scientific advisory board for the Michael J. Fox Foundation and has received honoraria for teaching from EMD Serono and speaking honoraria from Acorda Therapeutics.
Rights and permissions
About this article
Cite this article
Espay, A.J., Marras, C. Clinical Parkinson disease subtyping does not predict pathology. Nat Rev Neurol 15, 189–190 (2019). https://doi.org/10.1038/s41582-019-0153-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0153-9
This article is cited by
-
Reply to ‘Neuropathological progression of clinical Parkinson disease subtypes’
Nature Reviews Neurology (2019)
-
Neuropathological progression of clinical Parkinson disease subtypes
Nature Reviews Neurology (2019)